Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
Investing Experts Podcast 7.32K Follower s Subscribe Summary Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics. SpringWorks Therapeutics has promising data with multiple launches planned for next year. Tarsus Pharmaceuticals' lead drug shows strong launch metrics, suggesting significant upside potential despite its current market cap. AmyKerk Listen here or on the go via Apple Podcasts and Spotify Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and an early-stage pick, his #1 holding, SpringWorks Therapeutics (0:30). Data risk for Ogsiveo and Mirdametinib (5:50). This is an excerpt from a recent episode Jonathan's ROTY Biotech Community Transcript Rena Sherbill: Jonathan Faison , welcome to Investing Experts. Welcome to the Podcast. It's great to have you on the show. Jonathan Faison : Hey, thanks. Happy to be here, Rena. RS : You ru
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $63.00 to $65.00. They now have an "outperform" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business AchievementsGlobeNewswire
- Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors [Yahoo! Finance]Yahoo! Finance
TARS
Earnings
- 11/13/24 - Beat
TARS
Sec Filings
- 12/19/24 - Form 8-K
- 11/15/24 - Form 4
- 11/15/24 - Form 3
- TARS's page on the SEC website